BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26473950)

  • 21. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
    Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
    J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Semi-automated
    Keijzer K; Niezink AGH; de Boer JW; van Doesum JA; Noordzij W; van Meerten T; van Dijk LV
    Comput Struct Biotechnol J; 2023; 21():1102-1114. PubMed ID: 36789266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decisional early interim (18)F-fluoro-2-deoxy-D-glucose positron emission tomography after two cycles of chemotherapy in de novo Hodgkin lymphoma.
    Iltis A; Eder V; Blasco H; Colombat P; Sénécal D
    Acta Haematol; 2015; 133(2):172-8. PubMed ID: 25301496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limited Prognostic Value of SUV max Measured by F-18 FDG PET/CT in Newly Diagnosed Small Cell Lung Cancer Patients.
    Kim SJ; Chang S
    Oncol Res Treat; 2015; 38(11):577-85. PubMed ID: 26599271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
    Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positron Emission Tomography-Based Assessment of Metabolic Tumor Volume Predicts Survival after Autologous Hematopoietic Cell Transplantation for Hodgkin Lymphoma.
    Procházka V; Gawande RS; Cayci Z; Froelich JW; Cao Q; Wilke C; Dusenbery K; Weisdorf DJ; Bachanova V
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):64-70. PubMed ID: 28942016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SUV-measurements and patient-specific corrections in pediatric Hodgkin-lymphoma: is there a benefit for PPV in early response assessment by FDG-PET?
    Furth C; Meseck RM; Steffen IG; Schoenberger S; Denecke T; Henze G; Hautzel H; Hofheinz F; Großer O; Hundsdoerfer P; Amthauer H; Ruf J
    Pediatr Blood Cancer; 2012 Sep; 59(3):475-80. PubMed ID: 22190514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prognostic value of 18F-FDG PET-CT in Hodgkin lymphoma].
    Ying Z; Wang X; Song Y; Zheng W; Wang X; Xie Y; Lin N; Tu M; Ping L; Liu W; Deng L; Zhang C; Yang Z; Zhu J
    Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):325-7. PubMed ID: 24759021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma.
    Papajík T; Mysliveček M; Sedová Z; Buriánková E; Procházka V; Koranda P; Raida L; Kubová Z; Palová M; Kučerová L; Flodr P; Jarkovský J; Dušek L; Indrák K
    Eur J Haematol; 2011 Jan; 86(1):32-7. PubMed ID: 20874822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-D-glucose with positron emission tomography in patients with small cell lung cancer.
    Arslan N; Tuncel M; Kuzhan O; Alagoz E; Budakoglu B; Ozet A; Ozguven MA
    Ann Nucl Med; 2011 Jul; 25(6):406-13. PubMed ID: 21409347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer.
    Zhu D; Ma T; Niu Z; Zheng J; Han A; Zhao S; Yu J
    Lung Cancer; 2011 Sep; 73(3):332-7. PubMed ID: 21292341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome of Hodgkin Lymphoma Patients With a Posttreatment 18F-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography (FDG-PET)-Negative Residual Mass: Systematic Review and Meta-analysis.
    Adams HJ; Nievelstein RA; Kwee TC
    Pediatr Hematol Oncol; 2015; 32(8):515-24. PubMed ID: 26561044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can adaptive threshold-based metabolic tumor volume (MTV) and lean body mass corrected standard uptake value (SUL) predict prognosis in head and neck cancer patients treated with definitive radiotherapy/chemoradiotherapy?
    Akagunduz OO; Savas R; Yalman D; Kocacelebi K; Esassolak M
    Nucl Med Biol; 2015 Nov; 42(11):899-904. PubMed ID: 26275933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas.
    Lee SW; Nam SY; Im KC; Kim JS; Choi EK; Ahn SD; Park SH; Kim SY; Lee BJ; Kim JH
    Radiother Oncol; 2008 May; 87(2):211-6. PubMed ID: 18237806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
    Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
    J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Knogler T; Sillaber C; Jaeger U; Simonitsch-Klupp I; Ubl P; Müllauer L; Dolak W; Lukas J; Raderer M
    Clin Cancer Res; 2015 Jun; 21(11):2506-13. PubMed ID: 25733598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy.
    Jacene HA; Filice R; Kasecamp W; Wahl RL
    J Nucl Med; 2009 Jan; 50(1):8-17. PubMed ID: 19091903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.